Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer
Alison M. Schram(Memorial Sloan Kettering Cancer Center), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Cindy Neuzillet, Frans L. Opdam(The Netherlands Cancer Institute), Christoph Springfeld(Heidelberg University), Grainne M. O’Kane(University College Dublin), James M. Cleary(Brigham and Women's Hospital), Sun Young Rha(Yonsei University), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Lokesh Jain(Merus (Netherlands)), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Kōichi Goto(National Cancer Center Hospital East), Ernesto Wasserman(Merus (Netherlands)), M. Duruisseaux(Université Claude Bernard Lyon 1), Stephen V. Liu(Georgetown University), Shola Adeyemi(Merus (Netherlands)), Viktoriya Stalbovskaya(Novartis (Switzerland)), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Benjamin A. Weinberg(Georgetown University), Misako Nagasaka(University of California, Irvine), Kumiko Umemoto(St. Marianna University School of Medicine), Tanios Bekaii‐Saab(WinnMed), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Shekeab Jauhari(Merus (Netherlands)), Antoine Hollebecque(Institut Gustave Roussy), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Joon Oh Park(Samsung Medical Center), Dong-Wan Kim(Seoul National University Hospital), Kim A. Reiss(University of Pennsylvania), Andrew K. Joe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jim Ford(Merus (Netherlands))
Cited by 104
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k